ARTICLE | Company News
Gilead infectious, cardiovascular news
June 13, 2011 7:00 AM UTC
Atripla, a fixed-dose combination of Gilead's Truvada and Sustiva efavirenz from Bristol-Myers Squibb Co. (NYSE:BMY, New York, N.Y.), is co-marketed by the partners. Truvada is a fixed-dose combinat...